<p>Bayer AG has received its third regulatory approval in China for Nubeqa™ (darolutamide) for the treatment of men with advanced prostate cancer. The Chinese National Medical Products Administration (NMPA) approved the oral androgen receptor inhibitor (ARi) Nubeqa™ in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC). This approval is based on positive results from the Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT significantly reduced the risk of radiological progression or death compared to placebo plus ADT. Darolutamide is now the first and only ARi approved in China for use in combination with ADT, with or without chemotherapy, for this patient group. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on February 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

BAYN

ARKG

Reuters

Bayer AG

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

ALPS Medical Breakthrough

Bayer

iShares Biotechnology ETF

iShares US Pharma

VG Health

iShares Global Healthcare

China Approves Bayer’s Nubeqa for Advanced Prostate Cancer Treatment